Drug Trial Radar · NCT05672576
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
451
Actual
Start
Jun 26, 2023
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Viatris Innovation GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jan 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already being administered. In this research study approximately 210 participants will receive cenerimod and approximately 210 participants will receive placebo for 12 months.
Conditions
- Lupus Erythematosus, Systemic
Interventions
CenerimodDrug
Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.
PlaceboDrug
Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 12 compared to baselineTime frame: At Month 12 compared to Day 1 (pre-dose baseline)
Locations
147 sites in 18 countries. Site status is shown where the registry gives one.
Tucson Clinical Research Institute, LLC
Tucson, Arizona
UCSD Perlman Medical Offices
La Jolla, California
Amicis Research Center
Northridge, California
Hope Clinical Trials, Inc.
Coral Gables, Florida
Vital Pharma Research
Hialeah, Florida
Tectum Medical Research
Hollywood, Florida
Alloy Clinical Research, LLC
Kissimmee, Florida
Allied Biomedical Research Institute
Miami, Florida
D&H National Research Centers INC
Miami, Florida
Professional research Center INC
Miami, Florida
San Marcus Research Clinic, Inc.
Miami Lakes, Florida
Tandem Clinical Research
Marrero, Louisiana
RB Wellness Clinic
Las Vegas, Nevada
Columbia University Medical Center
New York, New York
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas
Texas Arthritis Center
El Paso, Texas
Northwest Houston Arthritis Center
Houston, Texas
Biomedica Research Group
Providencia, Chile
Sociedad Médica del Aparato Locomotor S. A.
Providencia, Chile
Estudios G y C Ltda
Santiago, Chile
Enroll SpA
Santiago, Chile
Centro de Especialidades Medicas Vanguardia
Temuco, Chile
Clinical Research Chile SpA
Valdivia, Chile
Hospital San José de Victoria
Victoria, Chile
iMedica s.r.o.
Brno, Czechia
Institute of Rheumatology Prague
Prague, Czechia
LTD "New Plasma Clinic"
Batumi, Georgia
Institute of Clinical Cardiology, Ltd
Tbilisi, Georgia
LTD "Tbilisi Central Hospital"
Tbilisi, Georgia
National Institute of Endocrinology Ltd.
Tbilisi, Georgia
Tbilisi Heart and Vascular Clinic Ltd.
Tbilisi, Georgia
Aversi Clinic LTD
Tbilisi, Georgia
Medi Club Georgia Ltd.
Tbilisi, Georgia
Tbilisi Institute of Medicine
Tbilisi, Georgia
JSC Jerarsi Clinic
Tbilisi, Georgia
Ltd. Mtskheta Street Clinic
Tbilisi, Georgia
The First Medical Center Ltd.
Tbilisi, Georgia
Caucasus Medical Centre
Tbilisi, Georgia
LLC "Innova"
Tbilisi, Georgia
LLC Raymann
Tbilisi, Georgia
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.